EUCTR2009-016812-18-IT进行中（未招募）不适用
Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes (VISTA-16) - VISTA-16
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 6,504
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Men and women =40 years of age
- •2. Written informed consent from the subject
- •3. A diagnosis of unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), or ST-segment
- •elevation myocardial infarction (STEMI)
- •4. All subjects (unstable angina, NSTEMI or STEMI) must have the presence of at least one of the following risk
- •i. Diabetes Mellitus
- •ii. Presence of any specified (see protocol) characteristics of metabolic syndrome.
- •iii. history of cerebrovascular disease (stroke or TIA) or
- •iv. history of peripheral vascular disease or
- •v. previous CABG or
- •vi. previous documented myocardial infarction or
- •vii. previous coronary revascularization or
- •5. Subjects must be randomized within =96 hours of hospital admission for the index event, or if already
- •hospitalized, within =96 hours of index event diagnosis
- •6. Revascularization, if required or planned, must occur prior to randomization.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to Screening.
- •2. Subjects treated for cancer within the previous 5 years except for skin basal cell carcinoma or carcinoma in situ of the cervix, with measures other than a minor, complete surgical excision or radiation therapy (e.g. chemotherapy)
- •3. The presence of any severe liver disease with cirrhosis, active hepatitis, active chronic hepatitis, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 x ULN, biliary obstruction with hyperbilirubinemia (total bilirubin >2 x ULN)
- •4. Active cholecystitis, gall bladder symptoms, or any hepatobiliary abnormalities
- •5. The presence of severe renal impairment (creatinine clearance [CrCl] <30 mL/min or creatinine >3 x ULN), nephrotic syndrome, or subjects undergoing dialysis
- •6. Uncontrolled diabetes mellitus (known hemoglobin A1c [HbA1c] >11% within the last 1 month prior to Screening)
- •7. Females who are nursing, pregnant, or intend to become pregnant during the time of the study, or females of childbearing potential who have a positive pregnancy test during screening evaluation. Women of child-bearing potential must also use a reliable method of birth control during the study and for 1 month following completion of therapy. A reliable method for this study is defined as one of the following: oral or injectable contraceptives, intrauterine device (IUD), contraceptive implants, tubal ligation, hysterectomy, a double barrier method (diaphragm with spermicidal foam or jelly, or a condom).
- •8. Subjects who have a history of alcohol or drug abuse within 1 year of study entry
- •9. Subjects living too far from participating center or unable to return for follow-up visits
- •10. Subjects who in the opinion of the Investigator are a poor medical or psychiatric risk for therapy with an investigational drug, are unreliable, or have an incomplete understanding of the study which may affect their ability to take drugs as prescribed or comply with instructions
- •11. Known human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), or tuberculosis infection
- •12. Acute bacterial, fungal or viral infection
- •13. Subjects currently taking drugs that are potent inhibitors of cytochrome P450 unless they can be withdrawn
- •14. Subjects with New York Heart Association (NYHA) Class III or IV heart failure, or if known, left ventricular ejection fraction (LVEF) <30
- •15. Subjects with moderate or severe aortic stenosis, aortic regurgitation, mitral stenosis or mitral regurgitation
- •16. Ventricular arrhythmias requiring chronic drug treatment or implantable cardioverter-defibrillator (ICD)
- •17. Subjects with no stenosis or stenosis <50% on angiography, if known
- •18. Subjects with a pacemaker or persistent left bundle branch block (LBBB)
- •19. Fasting triglyceride levels of =400 mg/dL (4.5 mmol/L)
- •20. Subjects who have a history of statin intolerance or a significant myopathy or rhabdomyolysis with any lipid altering drugs
- •21. Subjects currently treated with the maximum labeled dose of a statin and not at LDL-C target for their level of risk as defined by NCEP ATP.
研究者
相似试验
尚未招募
3 期
Evaluation of the Safety and Efficacy of Short-term A 002 Treatment in Subjects with Acute Coronary SyndromesHeart AttackHeart Disease10082206NL-OMON34504Anthera Pharmaceuticals, Inc576
进行中（未招募）
不适用
Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes - VISTA-16Treatment of patients with Acute Coronary Syndromes (ACS)MedDRA version: 12.1Level: LLTClassification code 10051592Term: Acute coronary syndromeEUCTR2009-016812-18-CZAnthera Pharmaceuticals, Inc.6,504
进行中（未招募）
不适用
Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes - VISTA-16Treatment of patients with Acute Coronary Syndromes (ACS)MedDRA version: 12.1Level: LLTClassification code 10051592Term: Acute coronary syndromeEUCTR2009-016812-18-DEAnthera Pharmaceuticals, Inc.6,504
进行中（未招募）
不适用
Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes - VISTA-16Treatment of patients with Acute Coronary Syndromes (ACS)MedDRA version: 12.1Level: LLTClassification code 10051592Term: Acute coronary syndromeEUCTR2009-016812-18-HUAnthera Pharmaceuticals, Inc.6,504
Unknown
3 期
A clinical trial to study the safety and efficacy of the study drug when added to atorvastatin plus standard of care in subjects with Acute Coronary syndromes (ACS).CTRI/2011/05/001713Anthera Pharmaceuticals Inc6,500